Institutional Ownership
Avalo Therapeutics Inc
CUSIP 05338F306COM NEWAVTXQ1 2026
13D / 13G Filings
46
Schedule 13D/13G on record
Beneficial Filers
23
Distinct reporting persons
Largest Stake
11.5%
Max % of class reported
Institutional Holders
93
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
46 filings · latest Mar 6, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Mar 6, 2026 | Fmr LLC | 13G | 11.5% | 2.13M | SEC |
| 2 | Feb 24, 2026 | Millennium Management LLC | 13G | 11.0% | 934.4K | SEC |
| 3 | Feb 17, 2026 | Caligan Partners LP | 13G/A | 4.9% | 881.5K | SEC |
| 4 | Feb 17, 2026 | Ra Capital Management, L.P. | 13G/A | 9.9% | 1.94M | SEC |
| 5 | Feb 17, 2026 | Balyasny Asset Management L.P. | 13G/A | 2.4% | 439.3K | SEC |
| 6 | Feb 17, 2026 | Millennium Management LLC | 13G | 11.0% | 887.3K | SEC |
| 7 | Feb 17, 2026 | Orbimed Advisors LLC | 13G/A | 6.4% | 1.19M | SEC |
| 8 | Feb 17, 2026 | Biotechnology Value Fund L P | 13G/A | 10.0% | 1.90M | SEC |
| 9 | Feb 17, 2026 | Point72 Asset Management, L.P. | 13G/A | 3.5% | 627.5K | SEC |
| 10 | Feb 10, 2026 | Millennium Management LLC | 13G | 11.0% | 906.8K | SEC |
36 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Avalo Therapeutics Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Fmr LLC | 2.88M | $42.99M |
| 2 | Caligan Partners LP | 1.64M | $24.41M |
| 3 | Bvf Inc/Il | 1.63M | $24.38M |
| 4 | Avoro Capital Advisors LLC | 1.41M | $21.05M |
| 5 | Affinity Asset Advisors, LLC | 1.34M | $20.02M |
| 6 | Nantahala Capital Management, LLC | 1.24M | $18.44M |
| 7 | Ubs Group AG | 1.14M | $17.05M |
| 8 | Point72 Asset Management, L.P. | 916.1K | $13.68M |
| 9 | Farallon Capital Management LLC | 916.0K | $13.68M |
| 10 | Rtw Investments, LP | 857.0K | $12.79M |